Madrigal Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 4/6
Madrigal Pharmaceuticals has a total shareholder equity of $777.2M and total debt of $117.1M, which brings its debt-to-equity ratio to 15.1%. Its total assets and total liabilities are $1.1B and $296.1M respectively.
Key information
15.1%
Debt to equity ratio
US$117.09m
Debt
| Interest coverage ratio | n/a |
| Cash | US$998.63m |
| Equity | US$777.16m |
| Total liabilities | US$296.11m |
| Total assets | US$1.07b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0JXI's short term assets ($1.1B) exceed its short term liabilities ($177.8M).
Long Term Liabilities: 0JXI's short term assets ($1.1B) exceed its long term liabilities ($118.3M).
Debt to Equity History and Analysis
Debt Level: 0JXI has more cash than its total debt.
Reducing Debt: 0JXI's debt to equity ratio has increased from 0% to 15.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0JXI has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 0JXI has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.